Nouscom
- Headquarters
- Rome
- Employees
- 11–50
- Founded
- 2015
- Business Model
- B2B
- Website
- nouscom.com
- Total Funding
- $82.0M
- Last Round
- $82.0M Series CMar 2024
About
Nouscom is a clinical-stage immuno-oncology company developing next-generation viral vector cancer vaccines based on neoantigens. Founded in 2015, the company's proprietary platform uses recombinant adenoviruses derived from non-human great apes (GAd) and MVA to generate potent anti-tumor immune responses, enabling both off-the-shelf and personalized cancer immunotherapies. Nouscom is headquartered in Basel, Switzerland, with research operations in Rome, Italy.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account